Vitamin A and Alzheimer's disease

Geriatrics and Gerontology International

Volumn 12, Issue 2, 2012, Pages 180-188

  Ono, Kenjiro ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Oligomer; VitaminA

Indexed keywords

AMYLOID BETA PROTEIN; BETA CAROTENE; RETINAL; RETINOIC ACID; RETINOL;

ALZHEIMER DISEASE; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; VITAMIN A; VITAMINS;

EID: 84859004158     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00786.x     Document Type: Review

References (91)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
2. Cacabelos R, Alvarez A, Lombardi A etal. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000; 36: 415-499.
3. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007; 6: 341-342.
4. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010; 88: 475-486.
5. Bayer AJ, Bullock R, Jones RW etal. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
6. Gilman S, Koller M, Black RS etal. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
7. Janus C, Pearson J, McLaurin J etal. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
8. Morgan D, Diamond DM, Gottschall PE etal. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
9. Orgogozo JM, Gilman S, Dartigues JF etal. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61: 46-54.
10. Schenk D, Barbour R, Dunn W etal. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
11. Chang WP, Huang X, Downs D etal. β-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 2011; 25: 775-784.
12. Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011; 69: 237-239.
13. Skovronsky DM, Lee VM. B-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease. Trends Pharmacol Sci 2000; 21: 161-163.
14. Vassar R, Bennett BD, Babu-Khan S etal. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741.
15. Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-411.
16. Czirr E, Weggen S. Gamma-secretase modulation with Aβ42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neurodegener Dis 2006; 3: 298-304.
17. Kukar TL, Ladd TB, Bann MA etal. Substrate-targeting gamma-secretase modulators. Nature 2008; 453: 925-929.
18. Reines SA, Block GA, Morris JC etal. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
19. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002; 59: 880-886.
20. Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 2002; 69: 567-577.
21. Walsh DM, Selkoe DJ. Aβ oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-1184.
22. Dev S, Adler AJ, Edwards RB. Adult rabbit brain synthesizes retinoic acid. Brain Res 1993; 632: 325-328.
23. McCaffery P, Drager UC. Hot spots of retinoic acid synthesis in the developing spinal cord. Proc Natl Acad Sci U S A 1994; 91: 7194-7197.
24. Zelent A, Mendelsohn C, Kastner P etal. Differentially expressed isoforms of the mouse retinoic acid receptor β generated by usage of two promoters and alternative splicing. EMBO J 1991; 10: 71-81.
25. Lee HP, Casadesus G, Zhu X etal. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother 2009; 9: 1615-1621.
26. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E etal. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30: 235-241.
27. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999; 92: 39-45.
28. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989; 35: 275-282.
29. Jimenez-Jimenez FJ, Molina JA, de Bustos F etal. Serum levels of β-carotene, α-carotene and vitamin A in patients with Alzheimer's disease. Eur J Neurol 1999; 6: 495-497.
30. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992; 21: 91-94.
31. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997; 45: 718-724.
32. Jama JW, Launer LJ, Witteman JC etal. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. Am J Epidemiol 1996; 144: 275-280.
33. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189: 380-392.
34. Takasaki J, Ono K, Yoshiike Y etal. Vitamin A has Anti-Oligomerization effects on Amyloid-β in vitro. J Alzheimers Dis 2011; 27: 271-280.
35. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-1135.
36. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890.
37. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987; 235: 877-880.
38. Kang J, Lemaire HG, Unterbeck A etal. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
39. Tanzi RE, Gusella JF, Watkins PC etal. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987; 235: 880-884.
40. Olson MI, Shaw CM. Presenile dementia and Alzheimer's disease in mongolism. Brain 1969; 92: 147-156.
41. Levy-Lahad E, Wasco W, Poorkaj P etal. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
42. Rogaev EI, Sherrington R, Rogaeva EA etal. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-778.
43. Sherrington R, Rogaev EI, Liang Y etal. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
44. De Strooper B, Saftig P, Craessaerts K etal. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-390.
45. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513-517.
46. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 1994; 13: 45-53.
47. Miller DL, Papayannopoulos IA, Styles J etal. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993; 301: 41-52.
48. Roher AE, Lowenson JD, Clarke S etal. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 10836-10840.
49. Golde TE, Eckman CB, Younkin SG. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 2000; 1502: 172-187.
50. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-4697.
51. McGowan E, Pickford F, Kim J etal. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005; 47: 191-199.
52. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
53. Ono K, Yamada M. Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem 2011; 117: 19-28.
54. Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002; 33: 182-191.
55. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
56. Mattson MP. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77: 1081-1132.
57. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73: 1055-1058.
58. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid β-protein. Proc Natl Acad Sci U S A 1997; 94: 7942-7947.
59. Naiki H, Gejyo F, Nakakuki K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 1997; 36: 6243-6250.
60. Ono K, Hamaguchi T, Naiki H, Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta 2006; 1762: 575-586.
61. Esler WP, Stimson ER, Ghilardi JR etal. In vitro growth of Alzheimer's disease β-amyloid plaques displays first-order kinetics. Biochemistry 1996; 35: 749-757.
62. Naiki H, Nakakuki K. First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab Invest 1996; 74: 374-383.
63. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272: 22364-22372.
64. Walsh DM, Hartley DM, Kusumoto Y etal. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999; 274: 25945-25952.
65. Hartley DM, Walsh DM, Ye CP etal. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-8884.
66. Podlisny MB, Ostaszewski BL, Squazzo SL etal. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995; 270: 9564-9570.
67. Walsh DM, Klyubin I, Fadeeva JV etal. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
68. Cleary JP, Walsh DM, Hofmeister JJ etal. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
69. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572: 477-492.
70. Shankar GM, Li S, Mehta TH etal. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
71. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62: 788-801.
72. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc Natl Acad Sci U S A 2009; 106: 14745-14750.
73. Oddo S, Caccamo A, Tran L etal. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 2006; 281: 1599-1604.
74. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009; 457: 1128-1132.
75. Balducci C, Beeg M, Stravalaci M etal. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 2010; 107: 2295-2300.
76. Calella AM, Farinelli M, Nuvolone M etal. Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol Med 2010; 2: 306-314.
77. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-β (Aβ) oligomers: role OF N-terminal residues. J Biol Chem 2010; 285: 26377-26383.
78. Freir DB, Nicoll AJ, Klyubin I etal. Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun 2011; 2: 336.
79. Szuts EZ, Harosi FI. Solubility of retinoids in water. Arch Biochem Biophys 1991; 287: 297-304.
80. Mitchell JJ, Paiva M, Heaton MB. Vitamin E and β-carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. Neurosci Lett 1999; 263: 189-192.
81. Mitchell JJ, Paiva M, Heaton MB. The antioxidants vitamin E and β-carotene protect against ethanol-induced neurotoxicity in embryonic rat hippocampal cultures. Alcohol 1999; 17: 163-168.
82. Ahlemeyer B, Krieglstein J. Inhibition of glutathione depletion by retinoic acid and tocopherol protects cultured neurons from staurosporine-induced oxidative stress and apoptosis. Neurochem Int 2000; 36: 1-5.
83. Sahin M, Karauzum SB, Perry G, Smith MA, Aliciguzel Y. Retinoic acid isomers protect hippocampal neurons from amyloid-β induced neurodegeneration. Neurotox Res 2005; 7: 243-250.
84. Misner DL, Jacobs S, Shimizu Y etal. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A 2001; 98: 11714-11719.
85. Cocco S, Diaz G, Stancampiano R etal. Vitamin A deficiency produces spatial learning and memory impairment in rats. Neuroscience 2002; 115: 475-482.
86. Etchamendy N, Enderlin V, Marighetto A, Pallet V, Higueret P, Jaffard R. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res 2003; 145: 37-49.
87. Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain. Eur J Neurosci 2004; 20: 896-902.
88. Ding Y, Qiao A, Wang Z etal. Retinoic acid attenuates β-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 2008; 28: 11622-11634.
89. Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A 2003; 100: 2901-2905.
90. Pardridge WM, Sakiyama R, Coty WA. Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. J Neurochem 1985; 44: 1138-1141.
91. Werner EA, Deluca HF. Retinoic acid is detected at relatively high levels in the CNS of adult rats. Am J Physiol Endocrinol Metab 2002; 282: E672-E678.